Drug companies were playing the role of Prozac to a gloomy European market on Wednesday, defying falling markets in the wake of Donald Trump's surprise victory on expectations that pricing pressure on medicines in the U.S. will ease and as investors piled into defensive stocks.

In the U.K., generics drug maker Hikma (HKMPF) was the second best performer in early trading on the FTSE 100, up almost 7%. It was joined in the U.K. index's top 10 gainers by branded drug makers Shire (SHPG) , up 5%, and AstraZeneca (AZN) , up 2.3%. The FTSE 100 as a whole was trading down 0.43%.

In France Sanofi (SNY) was up just over 2% making it just one of three companies to buck a fall in Paris's CAC 40, which was down 1.07%. In Germany, Bayer (BAYN) and Merck (MRK) were among the handful of rising stocks on the DAX, climbing 2.7% and 1.2% respectively despite the index's fall of just under 1%. Elsewhere, Denmark's Novo Nordisk (NVO) was up 6.4%, while Switzerland's Roche (RHHBY) was up just over 4%.

Trumps election is "a positive for the (pharmaceuticals) sector, with the bulk of industry hostile legislation now off the agenda," noted BNP Paribas analysts. "The threat of further pricing pressure has receded for the most part, but expect volatility."

Among Trump's election promises was a commitment to repeal the Affordable Health Care Act, better known as Obamacare. He had also said he would allow the sourcing of drugs from overseas markets, potentially putting pressure on U.S. pricing, though the Food and Drugs Administration has typically taken a dim view of this practice at a corporate level.

If you liked this article you might like

5 Things You Must Know Before the Market Opens Wednesday

European Stocks Rise as Oil Prices, Oil Stocks Gain

European Stocks Lower on Terror Worries

European Stocks Mixed, Asia Slumps Amid Weak China Manufacturing Data